» Articles » PMID: 23971850

Risk Factors Associated with Survival in Dogs with Nontonsillar Oral Squamous Cell Carcinoma 31 Cases (1990-2010)

Overview
Date 2013 Aug 27
PMID 23971850
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To identify risk factors associated with survival in dogs with nontonsillar oral squamous cell carcinoma (OSCC) that were and were not treated with curative-intent surgery.

Design: Retrospective case series.

Animals: 31 dogs with OSCC.

Procedures: Medical records for dogs with OSCC that were not treated, or were treated with curative-intent surgery only between January 1990 and December 2010 were reviewed. For each dog, data regarding signalment, clinical stage, treatment, tumor recurrence, and survival time were obtained from the medical record, and archived biopsy specimens were evaluated to identify the histologic subtype of the tumor and extent of tumor-associated inflammation (TAI), perineural invasion (PNI), and lymphovascular invasion (LVI).

Results: Risk of death for the 21 dogs with OSCC that were surgically treated was decreased 91.4% (hazard ratio, 0.086; 95% confidence interval, 0.002 to 0.150), compared with that for the 10 dogs with OSCC that were not treated. The 1-year survival rate was 93.5% and 0% for dogs that were and were not surgically treated, respectively. Risk of death increased significantly with increasing TAI and increasing risk score (combination of TAI, PNI, and LVI). Tumor location, clinical stage, and histologic subtype were not associated with survival time.

Conclusions And Clinical Relevance: Results indicated that the prognosis for dogs with OSCC was excellent following surgical excision of the tumor. Risk of death increased with increasing TAI, and combining TAI, PNI, and LVI into a single risk score may be a useful prognostic indicator for dogs with OSCC.

Citing Articles

The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma.

Katt W, Balkman C, Butler S, Byron M, Carney P, Todd-Donato A Sci Rep. 2025; 15(1):7069.

PMID: 40016294 PMC: 11868584. DOI: 10.1038/s41598-025-90574-3.


Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.

Aupperle-Lellbach H, Kehl A, de Brot S, van der Weyden L Vet Sci. 2024; 11(5).

PMID: 38787171 PMC: 11126050. DOI: 10.3390/vetsci11050199.


Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas.

Peralta S, Katt W, Balkman C, Butler S, Carney P, Todd-Donato A Res Sq. 2024; .

PMID: 38746473 PMC: 11092801. DOI: 10.21203/rs.3.rs-4289451/v1.


Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues.

Peralta S, Marcinczyk M, Katt W, Duhamel G Front Vet Sci. 2023; 10:1281022.

PMID: 37901104 PMC: 10611472. DOI: 10.3389/fvets.2023.1281022.


The diagnostic yield of preoperative screening for oral cancer in dogs over 15 years, part 1: locoregional screening.

Goldschmidt S, Soltero-Rivera M, Quiroz A, Wong K, Rebhun R, Zwingenberger A J Am Vet Med Assoc. 2023; 261(S2):S14-S23.

PMID: 37863103 PMC: 10956222. DOI: 10.2460/javma.23.05.0299.